<SEC-DOCUMENT>0000200406-17-000029.txt : 20170616
<SEC-HEADER>0000200406-17-000029.hdr.sgml : 20170616
<ACCEPTANCE-DATETIME>20170616063000
ACCESSION NUMBER:		0000200406-17-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170616
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170616
DATE AS OF CHANGE:		20170616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		17914774

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a20170616actelion.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s13803627d1324aad8f663f2444216507"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):&#160;&#160;June 16, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="jjlogoforwebfilinga05a02a02.jpg" alt="jjlogoforwebfilinga05a02a02.jpg" style="height:33px;width:178px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:35%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;08933</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;&#160;732-524-0400</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company    </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Completion of Acquisition or Disposition of Assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As previously disclosed, on January 26, 2017, Johnson&#160;&amp;&#160;Johnson, Cilag Holding AG, a Swiss corporation and wholly owned subsidiary of Johnson &amp; Johnson (the &#8220;Bidder&#8221;), and Janssen Holding GmbH, a Swiss corporation and wholly owned subsidiary of Johnson &amp; Johnson (the &#8220;Offeror&#8221;), entered into a Transaction Agreement (the &#8220;Transaction Agreement&#8221;) with Actelion Ltd, a Swiss corporation (&#8220;Actelion&#8221;).  Concurrently with the execution of the Transaction Agreement, Johnson &amp; Johnson, the Bidder and Actelion (and affiliates thereof, as applicable) entered into a Demerger Agreement (the &#8220;Demerger Agreement&#8221;) and certain other ancillary agreements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Transaction Agreement, the Offeror launched an all-cash tender offer in Switzerland to acquire all of the outstanding, publicly held shares, nominal value CHF 0.50 per share (the &#8220;Shares&#8221;), of Actelion for USD 280 per Share (the &#8220;Offer&#8221;).  The Offer expired at 4:00 p.m., CEST, on Thursday, April 21, 2017, upon which Johnson &amp; Johnson announced that 99,303,760 Shares were tendered into the Offer, representing approximately 92.51% of the Shares to which the Offer extended.  Following the expiration of the Offer, the remaining conditions to the Offer were satisfied and, on Friday, June 16, 2017, the Offeror completed the settlement of the Offer.  At settlement, the Offeror paid an aggregate consideration of USD 27,805,052,800 to holders of tendered Shares.  The payment was funded by an affiliate of Johnson &amp; Johnson from its available cash on hand.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the settlement of the Offer and pursuant to the Demerger Agreement, Actelion&#8217;s drug discovery operations and early-stage clinical development assets (and associated liabilities) were separated (the &#8220;Demerger&#8221;) into a newly-incorporated Swiss biopharmaceutical company, Idorsia Ltd (&#8220;Idorsia&#8221;).  All of the shares of Idorsia were distributed to Actelion&#8217;s shareholders as a dividend in kind immediately prior to the settlement of the Offer and were listed on the SIX Swiss Exchange.  Immediately following the Demerger, Idorsia had cash of CHF 1 billion, CHF 420 million of which was funded from cash on hand of Actelion and CHF 580 million of which was funded by an affiliate of Johnson &amp; Johnson by way of a convertible note facility with a tenor of ten years.  Following the initial conversion of the convertible note, which is expected to occur on June 19, 2017, the Bidder will hold 9.9% of the shares of Idorsia and, subject to certain limitations, will have the right to an additional 22.1% of Idorsia&#8217;s outstanding equity through the convertible note.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Offer, the Offeror became the majority owner of Actelion.  The Offeror intends to acquire the remaining untendered shares pursuant to a short-form merger or a squeeze-out procedure in accordance with Swiss law and takeover regulation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing description of the Offer and the Transaction Agreement is qualified in its entirety by reference to the Transaction Agreement, which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 1, 2017, and is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson issued a press release on June 16, 2017, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial statements of business acquired</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements required by Item 9.01(a) of Form 8-K will be filed by amendment within 71 calendar days after the date on which this Current Report on Form 8-K must be filed.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pro forma financial information.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma financial information required by Item 9.01(b) of Form 8-K will be filed by amendment within 71 calendar days after the date on which this Current Report on Form 8-K must be filed.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release announcing the settlement of the Offer and the consummation of the Demerger, dated as of June 16, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:7%;"></td><td style="width:33%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;&#160;June 16, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/S/ Thomas J. Spellman III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thomas J. Spellman III</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assistant General Counsel and</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:31%;"></td><td style="width:69%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release announcing the settlement of the Offer and the consummation of the Demerger, dated as of June 16, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20170616ex991-actelionpre.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sc3385bdf338449879ea340f5cbffd23b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;"><img src="jjlogoforwebfilinga05a02a02.jpg" alt="jjlogoforwebfilinga05a02a02.jpg" style="height:33px;width:178px;"></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Press Contacts:</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amy Jo Meyer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ernie Knewitz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 (732) 524-6678</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 (917) 697-2318</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ameyer15@its.jnj.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">eknewitz@its.jnj.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Relations Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Joseph J. Wolk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lesley Fishman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 (732) 524-1142</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 (732) 524-3922</font></div></td></tr></table></div></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson Announces Completion of Acquisition of Actelion</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction Expands Janssen Portfolio with </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leading Differentiated In-Market Medicines and Promising Late-Stage Therapies</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEW BRUNSWICK, N.J. - June 16, 2017 - </font><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson (NYSE:JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash. The acquisition was completed through an all-cash public tender offer by Johnson &amp; Johnson&#8217;s Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. Actelion will now become part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;We are very pleased to complete this compelling transaction and look forward to the value it will create for Johnson &amp; Johnson and for patients around the world suffering from pulmonary arterial hypertension (PAH) and other serious illnesses,&#8221; said Alex Gorsky, Chairman and Chief Executive Officer of Johnson &amp; Johnson. &#8220;Adding Actelion to our already strong pharmaceutical business expands our portfolio with leading, differentiated in-market medicines and promising late stage products. We are excited to welcome our new Actelion colleagues to the Johnson &amp; Johnson Family of Companies as we work together to improve the health of people around the world.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Through this transaction, Janssen will establish a sixth therapeutic area that will be a growth engine for us as our combined team builds on the market-leading position of Actelion&#8217;s therapies,&#8221; said Joaquin Duato, Executive Vice President and Worldwide Chairman, Pharmaceuticals, Johnson &amp; Johnson. &#8220;Actelion&#8217;s PAH franchise, including differentiated, innovative medicines Opsumit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Uptravi</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and Tracleer</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;1</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;expands our Janssen business and provides a leading commercial position in an established area of transformational medical innovation for patients with serious illnesses and significant unmet medical needs.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the completion of the public tender offer, Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd (SIX:IDIA). Shares of Idorsia were distributed to Actelion&#8217;s shareholders as a stock dividend and will begin trading on the SIX Swiss Exchange today. As previously announced, a subsidiary of Johnson &amp; Johnson will initially hold 9.9 percent of the shares of Idorsia and, subject to certain limitations, will have the right to an additional 22.1 percent of Idorsia&#8217;s outstanding equity through a convertible note. A subsidiary of Johnson &amp; Johnson also has an option on ACT-132577, a compound in development for resistant hypertension for which the phase 2 clinical results were recently announced.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson expects the transaction to add approximately $1.3 billion in sales for 2017 and be accretive to 2017 adjusted earnings per share by approximately $0.07. This impact was already included in the company's full-year sales and adjusted earnings per share guidance provided in April. Also, as previously disclosed, in the first full year after close, Johnson &amp; Johnson expects the transaction to be accretive to adjusted earnings per share by $0.35 to $0.40.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup>&#160;</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Johnson &amp; Johnson</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caring for the world, one person at a time, inspires and unites the people of Johnson &amp; Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 130,800 employees at more than 250 Johnson &amp; Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About the Janssen Pharmaceutical Companies of Johnson &amp; Johnson</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at </font><font style="font-family:inherit;font-size:10pt;color:#12c2e9;text-decoration:underline;">www.twitter.com/JanssenUS</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#12c2e9;text-decoration:underline;">www.twitter.com/JanssenGlobal</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Opsumit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(macitentan), Uptravi</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(selexipag) and Tracleer</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(bosentan) </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2 </sup></font><font style="font-family:inherit;font-size:10pt;">Adjusted earnings per share excludes intangible amortization expense and special items such as inventory step up, restructuring, integration, and other costs incurred to execute the transaction.  Adjusted EPS is a non-GAAP financial measure and should not be considered a replacement for GAAP results.  Johnson &amp; Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson &amp; Johnson&#8217;s results computed in accordance with GAAP.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This press release contains &#8220;forward-looking statements&#8221; as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Actelion Ltd. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &amp; Johnson. Risks and uncertainties include, but are not limited to: risks and uncertainties related to the ability of the Johnson &amp; Johnson family of companies to successfully integrate the products, employees/operations and clinical work of Actelion, as well as the ability to ensure continued performance or market growth of Actelion&#8217;s products; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; competition, including technological advances, new products and patents attained by competitors; adverse litigation or government action; challenges to patents; changes to applicable laws and regulations, including domestic and foreign health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson &amp; Johnson and Actelion can be found in Johnson &amp; Johnson&#8217;s publicly available filings with the U.S. Securities and Exchange Commission, and Actelion&#8217;s publicly available filings on its website. Copies of these filings, as well as subsequent filings, are available online at </font><font style="font-family:inherit;font-size:10pt;color:#12c2e9;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#12c2e9;text-decoration:underline;">www.jnj.com</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#12c2e9;text-decoration:underline;">www.actelion.com</font><font style="font-family:inherit;font-size:10pt;">&#32;or on request from Johnson &amp; Johnson. Johnson &amp; Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>jjlogoforwebfilinga05a02a02.jpg
<TEXT>
begin 644 jjlogoforwebfilinga05a02a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #7!&0# 2(  A$! Q$!_\0
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M48-!XKS'6OBF(YFCT>U615X\Z?(!^BC!Q]3^%9]C\5]4CF'VZSMIH<\^4"C
M>V2163K0N>G')\7*'-R_*^IZ_1@$5FZ1JUKK>GQWMFY,;]B,$$=01V-:5:)W
MU1YLHRA)QDK-"T444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXQ\3-4^W>)OLJ-F.S0)_P(\M_0?A3/AI )O&43D9\F*1Q[<;?_9JYB_NWO\
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MMUT^_P#X!Z(.M<]XUNA9>$-3DW8+1&,'W8[?ZUT-</\ %*Y\GPJL0ZS7")^
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M?,C> *XKQ1XZ7P_K=O8) )5(#7#$G**3V]\9/Y5UUU<Q6=K-<SL$BB0NY/8
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M,16QE796M]R_70])\!>'SH>A*TR;;NYQ)+GJ/[J_@/U)KD_BW_R$M-_ZY/\
MS%>KUY1\7/\ D):;_P!<G_F*VJKEIV1XN5UI5LP52>[O^1YS7<_"K_D:I_\
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M^C_2;_V2O,:].^+_ -_1_I-_[)7F-95OB9[.2_[E'Y_FSN?A5_R-5Q_UYO\
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MX8BU8W5_>(&A16AC4C(+,OS'\ ?UKAYX6M[B6%\;HW*''J#BO4O ?B32=/\
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M)79V8VK2R_">QI;O1=_-G4 <4445V'QQXS\5?^1J@_Z]$_\ 0WKAJ[GXK?\
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M3G.-CB*RC!^['\^H5Y/\7/\ D):;_P!<G_F*]8KR?XN?\A+3?^N3_P Q17^
MC)?]]C\_R/.:55+,%4$L3@ =325V'PZT(:KKXNIDS!9@2'(X+_PC^9_"N2*;
M=D?8XFO&A2E5ELCTOP;H']@:%% ZC[1)^\F/^T>WX# KH^]%%>A%)*R/SRK4
ME5FYRW9Y?\7_ +^C_2;_ -DKS&O3_B\C$:1(!\J^:"?<[,?R->85QUOC9]MD
MO^YQ^?YLVO#>O-X>N[J[B3=,]LT4>>@8LI!/L,&H='TNZ\2:ZELC%I9W+S2G
MG:,Y9C_GJ:S%4LP502Q. !U->X>!?#*Z!I"RS)_IUR TN>J#LGX=_>B$7-VZ
M$YCB*>#C*K%>_+1?UV1T6GV,&FV,-G;KLAB0(H]JM]J!17:E8^);<G=[GE?Q
M=_X^=*_W)?YK7FM>E?%[_CYTK_<E_FM>:UPU?C9]SD_^YP^?YA7MGPZT(Z3H
M"W,J8N;S$C9'(7^$?ES^->9>#]#.O>(8+=US;Q_O)CVVCM^)P*]]50H  P!T
M K2A#7F/-S_%VMAX]=7^@ZO-OBY_QY:9_P!=7_D*])KSGXMIG3=.DYXF9?S7
M_P"M6U7X&>/E/^^0^?Y,\GKH/!FJVVC>(H[Z[?9$D;]LDG:< ?6N?HKB3L[G
MW-6DJM-TY;-6-37-9N_$>LO=S*2SG9%$O.Q>RCU_J37L/@GPTOA[1U\T#[9/
MAYV]/1?P_GFN2^&_A,S2KKE['B)#_HR'^(]W^@[>_/85ZKQGI731A]MGRF;X
MR-EA:/PQW_R^1SOC;6&T7PS<3Q-MGEQ%$<X(9NX]P,G\*\8\/:.^N:W;V"DA
M';+L/X4'+'\OUKTGXLHYT*R<?<6YP?J5./ZUR/PYU2STOQ&YO'2-9H3$DKG
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M0X;08,Q&^9Q_$YZ_@.@^E<D5[2=^A]57JO+L#&DG[[_#O]QPOQ6LE@ETF2-
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M#4SIJ:U.O!XZKA)N5/KNCYUB\.ZU/,(DTJ]W^AA88^I(XKT3P=\/CI\R:EK
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M;5.7!/SL>C4445VGQ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SG
MC74?[+\*7TR'$KIY2?5N/T!)_"O%-!L/[3UZQL\ B650_P#NYRWZ UZ)\6[S
M;9:?9#_EI(TI'^Z,#_T(US?PRMA/XP1R,^3 \@]NB_\ LU<M3WJECZG+E[#+
MIUNKN_NT1[:HPH ]*6BBNH^6.'^*,RQ>%0A/,MPBC\ 3_2O)]$LCJ&N6-H%#
M"29 P/\ =SS^F:]!^+=X FFV0[L\QY], ?S-8_POTW[7XCDO&&4M(B0?]MN!
M^FZN2HN:I8^LP,OJ^6.H_-_HCV91\H^E+1176?)A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %-) !-+6/XFO3I_AR_N%.'2!]I_P!H
MC _4BDW97*A%SFHKJ>&>(M1.K>(;Z]SE9)3L.?X!POZ 5[/X&L18>$-/7&#*
MGG-[[N1^A%>$11M-*D2<L[!1]37TK;Q+#;11)]V-0H^@&*YJ"O)L^ESV2IT:
M=&.W^2M^I-44\@A@DD/15+'\!4A/45B>+KS[%X5U*?<%/DE%)]6^4?J:Z9:)
ML^;I1YYQBNKL?/S,SL68DL3DD]S7N_@*R^P^$+%3UE4S'_@1R/TQ7B&G6;ZC
MJ5M9H#NFE6,8[9/6OI"&-((4B085%"@>@' KGPZU;/I>(*MH0I+KK]Q-1117
M2?+A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'COQ6G+^([6#M';!O
MQ+-_@*D^$\>=:OI-H^6 +GTRP_P_2JGQ24CQ8A(X-JA'_?34OPOO5M_$\ENY
M ^TPE5SW8$''Y UR?\O?F?7<K>4VCV_X+/9Z.]':N?\ %FOIX>T66XR//<;8
M5/\ $Y[X]!U-=3:2NSY2E3E4FH1W9Y1\0=2&I>+;D(<QVX$"G/\ =^]_X\37
MHWPYTHZ;X7CFD7$MVWG'/93]T?ES^->5^&]'D\0^(8;5MS*S>9.^>=@.6.?4
M]/J:^@HXUCC5$4*JC  Z 5A17-)R9[^<58T:,,'#I:_R_P ]R2BBBN@^="BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 -[US?CJT:[\%Z@B_>1!*/\
M@+!C^@-=+4<L22PO$Z@JP*D'N#UI25TT:4:GLJD9KHT_N/F6NQ\._$*^T*Q%
MG-;K>0)_JP7V,@],X.1^%9/B?PW<^'=3DB9'-J6)AEQPR^F?4=Q6)7"G*+/O
MIPP^,I+F7-%ZG4^(_'6I>(8OLVT6MH?O11MDO_O-W'MQ6K\./"YO[T:Q=I_H
MT#?N58??D'?Z#^?TJIX6\ WVKSI<:A$]M8 Y.X;7E]@.P]_RS7LEM;0V=M';
MV\:QPQ@*J*, "MJ<')\TCPLQQE'#4GAL+UWMT_X)8[4445TGS04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 )TJG=Z98WX N[.WN,=/-B5\?F
M***3",FGH.M-/M+%-EK:P0+Z11A!^E6J**:&VV]1:***!!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!-!%<1[)8TD4]
M0R@@_@:J6VB:592;[;3K.%_[T<"J?S HHH:&IR6B9I8 HHHH$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
